Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491533 | 0.85 | CYP3A4 (0.56) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL9146862 | 0.81 | CYP3A4 (0.59) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL9609537 | 0.79 | CYP1A2 (0.57) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL2006250 | 0.78 | CYP1A2 (0.63) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL7820555 | 0.78 | CYP1A2 (0.63) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL19500874 | 0.77 | CYP19A1 (0.78) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL19472000 | 0.77 | CYP19A1 (0.78) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL8580709 | 0.77 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL3369590 | 0.77 | CRHBP (0.56) | ALDH1A1HSD17B10TDP1CYP3A4ATM | |
| SCHEMBL6064533 | 0.76 | KDM4E (0.58) | ALDH1A1HSD17B10TDP1CYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453004-B2 | Formylated xanthocillin analogues as neuroprotective agents | NEURON BIOPHARMA, S.A. (ES) | 2016-09-27 | — | — | US | disclosed |
| US-9453004-B2 | Formylated xanthocillin analogues as neuroprotective agents | NEURON BIOPHARMA, S.A. (ES) | 2016-09-27 | — | — | US | disclosed |
| US-9453004-B2 | Formylated xanthocillin analogues as neuroprotective agents | NEURON BIOPHARMA, S.A. (ES) | 2016-09-27 | — | — | US | disclosed |
| EP-2813222-B1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTANTS | NEURON BIOPHARMA SA (ES) | 2016-07-06 | — | — | EP | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | NEURON BIOPHARMA, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | NEURON BIOPHARMA, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | NEURON BIOPHARMA, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| EP-2813222-A2 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTANTS | Neuron Biopharma S.A. (ES) | 2014-12-17 | — | — | EP | disclosed |
| EP-1425010-A4 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-5182295-A | Miticides, fungicides | ROUSSEL UCLAF (FR) | 1993-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | ALDH1A1 1313/4885HSD17B10 3738/4885TDP1 2976/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | ALDH1A1 1690/4885HSD17B10 3516/4885TDP1 4442/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | ALDH1A1 1662/4885HSD17B10 3766/4885TDP1 4502/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | ALDH1A1 1656/4885HSD17B10 3464/4885TDP1 4443/4885 |
| US-20150011621-A1 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | FPR1, FPR2, FPR3 | ALDH1A1 4607/4885HSD17B10 2711/4885TDP1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.